Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Longitudinal Assessment
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Syngeneic Mouse Model
100%
Metastatic RCC
100%
Preclinical Therapy
100%
Renal Cell Carcinoma
50%
Renal Tumor
50%
United States
25%
Immune System
25%
Lung
25%
New Therapies
25%
Durable Response
25%
Tumor
25%
Tumor Growth
25%
Mouse Model
25%
Monoclonal Antibody
25%
Preclinical Testing
25%
Kidney
25%
Interleukin-2
25%
Multikinase Inhibitor
25%
Tumor Metastasis
25%
Sorafenib
25%
Treatment Protocol
25%
Interferon-α (IFN-α)
25%
Sunitinib
25%
Complete Remission
25%
Delayed Diagnosis
25%
Adenocarcinoma Cells
25%
Immunosuppressive Factors
25%
Intrarenal
25%
Median Survival Time
25%
Current Therapies
25%
Vascular Endothelial Growth Factor
25%
Effector Responses
25%
Human Condition
25%
Immune Effectors
25%
Reimplantation
25%
Renca
25%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
25%
Metastatic Site
25%
Renal Adenocarcinoma
25%
Multiple Metastases
25%
Novel Treatments
25%
Medicine and Dentistry
Metastatic Carcinoma
100%
Clear Cell Renal Cell Carcinoma
100%
Kidney Metastasis
100%
Kidney Tumour
100%
Lung
50%
Neoplasm
50%
Tumor Progression
50%
Sorafenib
50%
Sunitinib
50%
Median Survival Time
50%
Kidney Carcinoma
50%
Gamma Interferon
50%
Vasculotropin Receptor
50%
Adenocarcinoma Cell Line
50%
Immune System
50%
Immunosuppressive Drug
50%
Monoclonal Antibody
50%
Interleukin 2
50%